Clinical Trial Resource Center


Clinical Trial Resource Center

FDA Approved Drugs » Therapeutic Areas

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

FDA Approved Drugs by Therapeutic Area

Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Click on an area below to view the complete list of drugs in that category or review descriptions for our therapeutic area list to assist you in your search.

Find out more about the types of drugs included in this listing.

FDA Approved Drugs for Immunology

Drugs Approved in 2014

Grastek (Timothy Grass Pollen Allergen Extract); Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014

Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014

Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014

Ragwitek (Short Ragweed Pollen Allergen Extract); Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014

Drugs Approved in 2013

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Kineret, anakinra; Swedish Orphan Biovitrum; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved January 2013

Simponi (golimumab); Janssen Biotech; For the treatment of ulcerative colitis, Aproved May 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Tecfidera (dimethyl fumarate); Biogen Idec; For the treatment of relapsing multiple sclerosis, Approved March 2013

Tivicay (dolutegravir); ViiV HealthCare; For the treatment of HIV-1 in adults and children over 12 years of age, Approved August 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

Drugs Approved in 2012

Flucelvax, Influenza Virus Vaccine; Novartis; For the treatment of influenza virus subtypes A and type B, Approved November 2012

Fulyzaq (crofelemer); Salix Pharmaceuticals; For the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012

Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of postherpetic neuralgia, Approved June 2012

Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical; For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012

Rayos (prednisone) delayed-release tablets; Horizon Pharma; For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions, Approved July of 2012

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 infection, Approved August 2012

Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories; For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012

Drugs Approved in 2011

Arcapta (indacaterol maleate inhalation powder); Novartis; For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease, Approved July 2011

Benlysta (belimumab); Human Genome Sciences; For the treatment of systemic lupus erythematosus, Approved March 2011

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011

Daliresp (roflumilast); Forest Pharmaceuticals; For the treatment of chronic obstructive pulmonary disease, Approved February 2011

Dificid (fidaxomicin); Optimer Pharmaceuticals; For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011

Edurant (rilpivirine); Tibotec; For the treatment of HIV-1, Approved May 2011

Firazyr (icatibant); Shire Pharmaceuticals; For the treatment of acute attacks of hereditary angioedema, Approved August of 2011

Gralise (gabapentin); Abbott Laboratories; For the treatment of postherpetic neuralgia, Approved February 2011

Incivek (telaprevir); Vertex Pharmaceuticals; For the treatment of genotype 1 chronic hepatitis C, Approved May 2011

Nulojix (belatacept); Bristol-Myers Squibb; For the prevention of organ rejection following kidney transplant, Approved June 2011

Victrelis (boceprevir); Merck; For the treatment of chronic hepatitis C genotype 1, Approved May 2011

Drugs Approved in 2010

Cayston (aztreonam for inhalation solution); Gilead; For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa, Approved February 2010

Egrifta (tesamorelin for injection); Theratechnologies; For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010

Menveo (meningitis vaccine); Novartis; For the active immunization to prevent invasive meningococcal disease, Approved February 2010

Oravig (miconazole); Strativa Pharmaceuticals; oropharyngeal candidiasis, Approved April 2010

Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine); Wyeth; For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae, Approved February 2010

Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010

Zortress (everolimus); Novartis; For the prevention of organ rejection following kidney transplant, Approved May 2010

Zymaxid (gatifloxacin ophthalmic solution); Allergan; For the treatment of bacterial conjunctivitis, Approved May 2010

Drugs Approved in 2009

Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009

Berinert (C1 Esterase Inhibitor (Human)); CSL Behring; For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009

Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb; For the treatment of bacterial conjunctivitis, Approved June 2009

Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline; For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009

Coartem (artemether/lumefantrine); Novartis; For the treatment of malaria infections due to Plasmodium falciparum, Approved April 2009

Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline; For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009

Ilaris (canakinumab); Novartis; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved June 2009

Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Intercell AG; For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009

Kalbitor (ecallantide); Dyax; For the treatment of hereditary angioedema, Approved November 2009

Qutenza (capsaicin); NeurogesX; For the treatment of neuropathic pain associated with postherpetic neuralgia, Approved November 2009

Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009

Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics; For the treatment of acute herpetic keratitis, Approved September 2009

Drugs Approved in 2008

Aptivus (tipranavir); Boehringer Ingelheim; For the treatment of HIV, Approved June 2008

Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008

Cinryze (C1 Inhibitor (Human)); Lev Pharmaceuticals; For the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema, Approved October 2008

Intelence (etravirine); Tibotec; For the treatment of HIV-1, Approved January 2008

Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008

Rotarix (Rotavirus Vaccine, Live, Oral); GlaxoSmithKline; For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics, Approved April 2008

Tysabri (natalizumab); Biogen IDEC; For the maintenance treatment of moderate to severe Crohn’s disease, Approved January 2008

Viread (tenofovir disoproxil fumarate); Gilead; For the treatment of hepatitis B, Approved August 2008

Drugs Approved in 2007

Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007

AzaSite (azithromycin); InSite Vision; For the treatment of bacterial conjunctivitis, Approved April 2007

Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007

Extina (ketoconazole); Stiefel; For the treatment of seborrheic dermatitis, Approved June 2007

Isentress (raltegravir); Merck; For the treatment of HIV-1, Approved October 2007

Selzentry (maraviroc); Pfizer; For the treatment of CCR5-tropic HIV-1, Approved August 2007

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Drugs Approved in 2006

Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006

Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck; For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006

Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006

Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006

Rotateq (rotavirus vaccine, live oral pentavalent); Merck; For the prevention of gastroenteritis associated with rotavirus infections in infants, Approved February 2006

Tyzeka (telbivudine); Idenix Pharma; For the treatment of hepatitis B virus, Approved October 2006

Veregen (kunecatechins); Medigene; For the treatment of external genital and perianal warts, Approved October 2006

Drugs Approved in 2005

Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005

Baraclude (entecavir); Bristol-Myers Squibb; For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Drugs Approved in 2004

Ketek (telithromycin); Sanofi-aventis; For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia., Approved April 2004

Tindamax, tinidazole; Presutti Laboratories; For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis, Approved May, 2004

Xifaxan (rifaximin); Salix Pharmaceuticals; For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli, Approved May 2004

Drugs Approved in 2003

Amevive (alefacept); Biogen IDEC; For moderate to severe chronic plaque psoriasis., Approved January 2003

FluMist ( Influenza Virus Vaccine); MedImmune; For the prevention of disease caused by influenza A and B viruses, Approved June 2003

Fuzeon (enfuvirtide); Trimeris, Roche; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003

Lexiva (fosamprenavir calcium); GlaxoSmithKline; For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003

Reyataz (atazanavir sulfate); Bristol-Myers Squibb; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003

Drugs Approved in 2002

Alinia (nitazoxanide); Romark Laboratories; For the treatment Diarrhea caused by Cryptosporidium and Giardia in children., December 2002

Clarinex; Schering-Plough; Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002

Daptacel; Sanofi Pasteur; Pediatric vaccine for immunization against diptheria, tetanus and pertussis, Approved May 2002

Fluzone Preservative-free; Sanofi Pasteur; Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002

Hepsera (adefovir dipivoxil); Gilead; For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002

Pediarix Vaccine; GlaxoSmithKline; For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old., Approved December 2002

Pegasys (peginterferon alfa-2a); Roche; For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002

Restasis (cyclosporine ophthalmic emulsion); Allergan; For the treatment of low tear production., December 2002

Sustiva; Bristol-Myers Squibb; Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002

Vfend (voriconazole); Pfizer; For the treatment of fungal infections, Approved May 2002

Drugs Approved in 2001

Avelox I.V. (moxifloxacin hydrochloride); Bayer; Injectable antibacterial agent for adults with susceptible strains of bacterial infections, Approved November 2001

Cancidas; Merck; Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001

Peg-Intron (peginterferon alfa-2b); Schering-Plough; For the treatment of chronic hepatitis C, Approved January 2001

Rebetol (ribavirin); Schering-Plough; For the treatment of chronic hepatitis C, Approved July 2001

Spectracef; TAP Pharmaceuticals; Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001

Twinrix; GlaxoSmithKline; For the prevention of hepatitis A and B, Approved May 2001

Valcyte (valganciclovir HCl); Roche; For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001

Viread (tenofovir disoproxil fumarate); Gilead; Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001

Xigris (drotrecogin alfa [activated]); Eli Lilly; For the treatment of severe sepsis, Approved November 2001

Drugs Approved in 2000

ABREVA (docosanol); AVANIR PHARMACEUTICALS; Cold sore/fever blister, Approved July 2000

Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories; For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000

Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000

Children's Motrin Cold; McNeil Consumer Products; For temporary relief of the common cold, Approved August 2000

Evoxac; SnowBrand Pharmaceuticals; For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome, Approved January 2000

Kaletra Capsules and Oral Solution; Abbott Laboratories; For the treatment of HIV-1 infection, Approved September 2000

Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis; For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000

Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough; For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000

Malarone (atovaquone; proguanil hydrochloride) Tablet; GlaxoSmithKline; For the treatment and prevention of Plasmodium falciparum malaria, Approved July 2000

Rapamune (sirolimus) Tablets; Wyeth; For treatment of kidney rejection, Approved August 2000

Rid Mousse; Soltec Research; For the treatment of head, pubic (crab), and body lice, Approved March 2000

Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical; For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000

Trivagizole 3 (clotrimazole) Vaginal Cream; Taro Pharmaceuticals; For the treatment of vaginal yeast infections, Approved April 2000

Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline; For the treatment of HIV-1 infection, Approved November 2000

Drugs Approved in 1999

Agenerase (amprenavir); GlaxoSmithKline; For the treatment of HIV-1 infection., Approved April 1999

Cleocin (clindamycin phosphate); Pharmacia & Upjohn; Treatment for bacterial vaginosis, Approved August 1999

Famvir (famciclovir); SmithKline Beecham; Treatment for Herpes Simplex Infections in HIV-infected patients, Approved January 1999

Norvir (ritonavir); Abbott Laboratories; Treatment for HIV infection, Approved June 1999

Panretin Gel; Ligand Pharmaceuticals; Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma., Approved June 1999

Rapamune (sirolimus) oral solution; Wyeth; Oral solution of sirolimus, Approved September 1999

Relenza; GlaxoSmithKline; Treatment for uncomplicated acute illness due to influenza virus, Approved July 1999

Synercid I.V.; Rhone Poulenc Rorer; quinupristin and dalfopristin for injection, Approved September 1999

Tamiflu capsule; Roche; Oseltamivir phosphate capsule, October 27, 1999

Vistide (cidofovir); Gilead; For the treatment of cytomegalovirus (CMV) retinitis, Approved March 1999

Drugs Approved in 1998

Allegra-D; Hoechst Marion Roussel; Treatment for nasal congestion due to seasonal allergy, Approved March 1998

CellCept; Roche; Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998

Clemastine fumarate syrup; Morton Grove Pharmaceuticals; Generic equivalent of Tavist Syrup, Approved March 1998

Cleocin (clindamycin phosphate); Pharmacia & Upjohn; Treatment for bacterial vaginosis, Approved March 1998

Dynabac; Sanofi-aventis; Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998

REBETRON (TM) Combination Therapy; Schering-Plough; Treatment for Chronic Hepatitis C, Approved June 1998

Simulect; Novartis; Treatment for acute organ transplant rejection, Approved May 1998

Timentin; SmithKline Beecham; Treatment for wide range of infections in children, Approved January 1998

Viroptic; King Pharmaceuticals; Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998

Drugs Approved in 1997

INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham; Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997

Acyclovir Capsules; Teva Pharmaceutical; Generic equivalent of Zovirax, Approved April 1997

Aldara (imiquimod); 3M Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997

Aphthasol; Block Drug Company; Treatment for canker sores, Approved December 1997

Combivir; GlaxoSmithKline; Treatment for AIDS and HIV Infection, Approved September 1997

Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997

Famvir (famciclovir); SmithKline Beecham; Treatment for genital herpes, Approved September 17, 1997

Flagyl ER; Searle; Treatment for bacterial vaginosis, Approved December 1997

Flonase Nasal Spray; GlaxoSmithKline; Treatment for seasonal and perennial allergic rhinitis, Approved November 1997

Fortovase; Roche; Treatment for HIV infection, Approved November 1997

INFERGEN (interferon alfacon-1); Amgen; Treatment for chronic hepatitis C virus, Approved October 1997

Intron A (interferon alfa-2b, recombinant); Schering-Plough; Treatment for hepatitis C, Approved March 1997

Norvir (ritonavir); Abbott Laboratories; Treatment for HIV infection, Approved March 1996/March 1997

Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn; Treatment for HIV-1 infection, Approved April 1997

SPORANOX (itraconazole); Janssen Pharmaceuticals; Treatment for oral thrush, Approved March 1997

Stromectol (ivermectin); Merck; Treatment for nondisseminated intestinal threadworm, Approved March 1997

Taxol; Bristol-Myers Squibb; Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997

Trovan; Pfizer; Treatment for bacterial infections, Approved December 1997

VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals; Treatment for HIV infection in adults and children, Approved March 1997

Zerit (stavudine); Bristol-Myers Squibb; Treatment for infants and children infected with HIV, Approved January 1997

Drugs Approved in 1996

Albenza (albendazole); SmithKline Beecham; Treatment for parasitic infections caused by worms, Approved June 1996

Apthasol (Amlexanox); Access Pharmaceuticals; Treatment for canker sores, Approved May 1996

Carrington patch; Carrington Laboratories; Treatment for canker sores, Approved May 1996

Confide; Johnson & Johnson; HIV testing and counseling service, Approved May 1996

Crixivan (Indinavir sulfate); Merck; Treatment for HIV infection, Approved March 1996

Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer; Treatment for mastocytosis, Approved April 1996

Havrix; SmithKline Beecham; Treatment for hepatitis A, Approved March 1996

Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals; Treatment for nail fungal infections, Approved May 1996

Leukine (sargramostim); Immunex; Treatment for the replenishment of white blood cells, Approved November 1996

Oral Cytovene; Roche; Treatment for the prevention of cytomegalovirus (CMV), Approved December 1996

RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune; Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996

Videx (didanosine); Bristol-Myers Squibb; Treatment of HIV infection, Approved June 1996

Viramune (nevirapine); Boehringer Ingelheim; Treatment for HIV infection, Approved June 1996

Vistide (cidofovir); Gilead; Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996

Vitrasert Implant; Chiron; Drug delivery system for the treatment of cytomegalovirus, Approved March 1996

Zithromax (azithromycin); Pfizer; Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996

Drugs Approved in 1995

Cedax (ceftibuten); Schering-Plough; Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995

Clarithromycin (Biaxin); Abbott Laboratories; Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995

Epivir (lamivudine); GlaxoSmithKline; Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995

Intron A (Interferon alfa-2b, recombinant); Schering-Plough; An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995

Invirase (saquinavir); Roche; Treatment for HIV/AIDS, Approved on December 7, 1995

Valtrex (valacyclovir HCl); GlaxoSmithKline; Treatment for recurrent genital herpes, Approved December 1995

Western blot confirmatory device; Epitope; Confirmatory test for HIV, Approved in December 1995

Zerit (stavudine); Bristol-Myers Squibb; Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995

Zyrtec (cetirizine HCl); Pfizer; Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995